Milestone Q2 Net Loss Expands; ReVeRA-301 Phase 3 Trial Of Etripamil Open For Enrollment; Stock Down

Milestone Pharmaceuticals Inc. (MIST), a biopharmaceutical company, announced financial results for the second quarter, reflecting a wider net loss and provided an update on its regulatory and clinical programs.